Risks and Benefits of Naloxone Prescribing

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

405 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-07-31

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This investigation is one of the first large-scale, prospective attempts to obtain data on the effectiveness of naloxone distribution among opioid-abusing populations at high risk of unintentional opioid poisoning. Specifically, opioid abusers will be recruited from drug detoxification sites as well as those accessing services at needle exchange programs. All participants (N=700) will receive the standard opioid overdose education and naloxone. One third of the participants will be randomized to receive additional in-depth psychosocial education focusing on recognition and prevention of opioid overdose, and appropriate use of naloxone. Another third of the participants will receive the extensive training and be required to engage a spouse, partner, relative, or friend in this supplementary intervention. The investigators plan to randomize individuals to each group \[Treatment as Usual (TAU) vs. Extensively Trained (ET) vs. Extensively Trained with a Significant Other (ETwSO)\] and, through continued follow up over one year, the investigators will compare self-reported overdose reversal attempts (with and without naloxone use), naloxone-related adverse events, and changes in patterns of heroin and other drug use.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Direct Outreach to Expand Access to Naloxone in the Context of Standing Orders

NCT03241771

Opioid Abuse Overdose Risk Behavior

COMPLETED NA

Smartphones for Opiate Addiction Recovery

NCT05033028

Opioid-use Disorder

RECRUITING PHASE3

Medication-Assisted Treatment for Youth With Substance Use Disorders

NCT02593474

Opioid Use Disorder Opioid Dependence

COMPLETED PHASE1

Clinical Decision Support to Improve System Naloxone Co-prescribing

NCT06271668

Medication Abuse Harm Reduction Opioid Overdose +1 more

ENROLLING_BY_INVITATION

Addressing Overdose Risk Among Recently Incarcerated People Living With HIV/AIDS

NCT03569592

Drug Overdose Accidental

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Design A significant cause of mortality among opioid users is overdose, which commonly occurs following voluntary (opioid detoxification) or involuntary (incarceration) opioid abstinence. For the purposes of the current application, opioid overdose is defined as use of an opioid in an amount that results in over-sedation and/or respiratory depression requiring intervention by medical or non-medical persons. Nearly 85% of overdoses occur in the presence of a witness. Common methods of intervention by individuals without medical training are ineffective techniques such as shaking the victim or injecting salt water. Naloxone is an opioid antagonist that has long been used successfully by trained medical personnel during emergency resuscitation following opioid overdose. In an effort to reduce fatal and non-fatal opioid overdose, a number of states are implementing programs in which non-medical personnel are provided brief instruction in recognizing the signs of opioid overdose and administering naloxone. However, most of the existing programs are not designed to collect empirical data on the safety and effectiveness of this intervention. Reporting of naloxone use is voluntary and without incentive, and the experience of those who have been trained and prescribed naloxone is not followed.

The proposed investigation will be one of the first large-scale, prospective attempts to obtain data on the effectiveness of naloxone distribution among opioid-abusing populations at high risk of unintentional opioid poisoning. Specifically, opioid abusers will be recruited from drug detoxification sites as well as those accessing services at needle exchange programs. All participants (N=700) will receive the standard opioid overdose education and naloxone. One third of the participants will be randomized to receive additional in-depth psychosocial education focusing on recognition and prevention of opioid overdose, and appropriate use of naloxone. Another third of the participants will receive the extensive training and be required to engage a spouse, partner, relative, or friend in this supplementary intervention. We plan to randomize individuals to each group \[Treatment as Usual (TAU) vs. Extensively Trained (ET) vs. Extensively Trained with a Significant Other (ETwSO)\] and, through continued follow up over one year, we will compare self-reported overdose reversal attempts (with and without naloxone use), naloxone-related adverse events, and changes in patterns of heroin and other drug use. In addition to comparing outcome variables in the TAU, ET and ETwSO groups prospectively, we will analyze data collected before study initiation to compare fatal and non-fatal opioid overdose rates in neighborhoods with facilities that offer overdose prevention training and naloxone to those that do not, using data provided by our collaborators at the New York City (NYC) Department of Health and Mental Hygiene (DOHMH).

Specific Aims and Hypotheses

* Primary Aim (Prospective Study): Determine the extent to which additional psychosocial intervention can improve the effectiveness of current overdose prevention training as measured by:
* increased frequency of naloxone use (ETwSO \> ET \> TAU)
* decreased number of opioid overdoses (ETwSO \< ET \< TAU)
* improved recognition of opioid overdose and naloxone indication knowledge (increased BORRA scores; ETwSO \> ET \> TAU)
* Secondary Aim (Prospective Study): Determine the potential harms of this novel naloxone-prescribing practice as measured by:
* proportion of participants calling 911 in response to an overdose, compared to participants' recent history of calling 911 in response to an overdose
* risky drug use behavior (e.g. increased heroin/prescription opioid use, increased use of illicit drug combinations) following training, compared to pre-training

Outcome Measures

Primary Outcome Measures (Prospective Study): Determine the extent to which additional psychosocial intervention can improve upon the effectiveness of current overdose prevention training by: 1) increasing the frequency of naloxone use among ET participants (continuous variable); 2) decreasing the number of lethal opioid overdoses witnessed and experienced by the ET group (continuous variable); 3) improving accurate recognition of opioid overdose and naloxone indication knowledge (increased Brief Overdose Recognition and Response Assessment (BORRA) score among ET participants (continuous variable). These variables will be assessed repeatedly over the course of 1 year at: baseline (BL), immediately post-training (T0), 1-, 3-, 6- and 12-months (T1, T3, T6, and T12). The frequency of naloxone use and outcomes of the overdose reversal attempts will be measured at T1, T3, T6, and T12 only.

Secondary Outcome Measures (Prospective Study): Evaluate the potential harms of this novel naloxone-prescribing practice as assessed by: 1) decreased proportion of 911 calls in response to an overdose, compared to participants' previous history of calling 911 while witnessing an overdose (continuous variable); 2) changes in the use of illicit opioids, other illegal drugs, or drug combinations following training (longitudinal continuous variable); 3) prevalence of adverse events related to naloxone administration by non-medical personnel (continuous variable).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Overdose

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Training

Participants receive our standard overdose training.

Group Type NO_INTERVENTION

No interventions assigned to this group

Extensive Training

Participant receives an more in-depth, extensive training concerning opioid overdose.

Group Type EXPERIMENTAL

Extensive training

Intervention Type OTHER

We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.

Extensive Training w/ Significant Other

Participant and their significant other both receive a more in-depth, extensive training concerning opioid overdose.

Group Type EXPERIMENTAL

Extensive training

Intervention Type OTHER

We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extensive training

We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 21 to 65 years
* Has met DSM-V criteria for moderate-severe opioid use disorder within the past 6-months, actively using heroin, prescription opioids, or has detoxified within the last 3 months.
* In otherwise good health based on medical history and laboratory tests
* Able to provide informed consent and comply with study procedures
* Able to fluently speak and read English
* Able to identify a spouse, friend or relative who willing to serve as their "significant other"

Exclusion Criteria

* Active psychiatric disorder that might interfere with participation or make participation hazardous, including DSM-V organic mental disorder, psychotic disorder, or bipolar disorder with mania
* Previous Basic Cardiac Life Support or First-Aid training
* Active treatment with extended-release naltrexone (Vivitrol) for alcohol or opioid dependence
* Naloxone training for opioid overdose prevention in the previous 2 years (Clinical Interview)

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No